Phosphoramidate prodrugs of (-)-β-D-(2R,4R)-dioxolane-thymine (DOT) as potent anti-HIV agents

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 5, 2012, Pages 217-238

  Wang, Peiyuan ^a   Rachakonda, Suguna ^a   Zennou, Veronique ^a   Keilman, Meg ^a   Niu, Congrong ^a   Bao, Donghui ^a   Ross, Bruce S ^a   Furman, Phillip A ^a   Otto, Michael J ^a   Sofa, Michael J ^a  

^a PHARMASSET INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DAXTRO DIOXOLANE THYMINE 5' (2 4 DICHLOROPHENYL BUTYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (2 4 DICHLOROPHENYL ETHYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (2 4 DICHLOROPHENYL ISOPROPYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (2 CHLOROPHENYL ISOPROPYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (3 4 DICHLOROPHENYL METHOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 BROMOPHENYL BENZYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 BROMOPHENYL HEXYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 BROMOPHENYL ISOPROPYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 BROMOPHENYL N BUTYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 BROMOPHENYL PENTYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 BROMOPHENYL TERT BUTYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 FLUOROPHENYL ETHYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 FLUOROPHENYL ISO PROPYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 METHOXYPHENYL BENZYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (4 METHYLPHENYL BENZYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (NAPHTHALENYLETHOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (PHENYL HEXYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (PHENYL N BUTYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (PHENYL PENTYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (PHENYL SEC BUTHYLOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (PHENYLETHOXY ALANYL PHOSPHATE); DAXTRO DIOXOLANE THYMINE 5' (PHENYLISOPROPYLOXY ALANYL PHOSPHATE); DIOXOLANE THYMINE 5' (NAPHTHALENYLETHOXY ALANYL PHOSPHATE); DIOXOLANE THYMINE 5' (PHENYL N BUTYLOXY ALANYL PHOSPHATE); DIOXOLANE THYMINE 5' (PHENYLISOPROPYLOXY ALANYL PHOSPHATE); PHOSPHORAMIDATE PRODRUG; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ANALYSIS; DRUG METABOLISM; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; ENANTIOMER; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE FLUID; LIVER; PLASMA; PRIORITY JOURNAL; STOMACH JUICE; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

AMIDES; ANTI-HIV AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIOXOLANES; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PHOSPHORIC ACIDS; PRODRUGS; SPECTROPHOTOMETRY, ULTRAVIOLET; THYMINE;

EID: 84863098141     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP2079     Document Type: Article

References (21)

1. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010; 53:521-538.
2. De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005; 48:1297-1313.
3. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317:192-197.
4. Starnes MC, Cheng YC. Celluar, metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodefciency virus in vitro. J Biol Chem 1987; 252:988-991.
5. Petersen EA, Ramírez-Ronda CH, Hardy WD, et al. Dose related activity of stavudine in patients infected with human immunodefeciency virus. J Infect Dis 1995; 171 Suppl 2:S131-S139.
6. Lennerstrand J, Chu CK, Schinazi RF. Biochemical studies on the mechanism of human immunodefciency virus type 1 reverse transcriptase resistance to 1-(beta-d-dioxolane) thymine triphosphate. Antimicrob Agents Chemother 2007; 51:2078-2084.
7. Chu CK, Yadav V, Chong YH, Schinazi RF. Anti-HIV activity of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)-thymine against drug-resistant HIV-1 mutants and studies of its molecular mechanism. J Med Chem 2005; 48:3949-3952.
8. Deville-Bonne D, El Amri C, Meyer P, Chen Y, Agrofoglio LA, Janin J. Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: structural and catalytic properties. Antiviral Res 2010; 86:101-120.
9. McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J Med Chem 1996; 39:1748-1753.
10. Balzarini J, Kruining J, Wedgwood O, et al. Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodefeciency virus and hepatitis B virus. FEBS Lett 1997; 410:324-328.
11. McGuigan C, Harris SA, Daluge SM, et al. Application of phosphoramidate pronucleotide technology to abacavir leads to a significant enhancement of antiviral potency. J Med Chem 2005; 48:3504-3515.
12. McGuigan C, Sutton PW, Cahard D, et al. Synthesis, anti-human immunodefeciency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). Antivir Chem Chemother 1998; 9:473-479.
13. Liang Y, Narayanasamy J, Schinazi RF, Chu CK. Phosphoramidate and phosphate prodrugs of (-)-beta-d-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies. Bioorg Med Chem 2006; 14:2178-2189.
14. Lehsten DM, Baehr DN, Lobl TJ, Vaino AR. An improved procedure for the synthesis of nucleoside phosphoramidates. Org Process Res Dev 2002; 6:819-822.
15. Charneau P, Alizon M, Clavel F. A second origin of DNA plus-strand synthesis is required for optimal human immunodefeciency virus replication. J Virol 1992; 66:2814-2820.
16. Sofa MJ, Bao D, Chang W, et al. Discovery of a p-d-2'-deoxy-2'-a-Fluoro-2'-p-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of HCV. J Med Chem 2010; 53:7202-7218.
17. McGuigan C, Thiery JC, Daverio F, Jiang WG, Davies G, Mason M. Anti-cancer ProTides: tuning the activity of BVDU phosphoramidates related to thymectacin. Bioorg Med Chem 2005; 13:3219-3227.
18. Siddiqui AQ, Ballatore C, McGuigan C, De Clercq E, Balzarini J. The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: a structure activity relationship. J Med Chem 1999; 42:393-399.
19. McGuigan C, Pathirana RN, Mahmood N, Devine KG, Hay AJ. Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT. Antiviral Res 1992; 17:311-321.
20. McGuigan C, Madela K, Aljarah M, et al. Dual pro-drugs of 2'-C-methyl guanosine monophosphate as potent and selective inhibitors of hepatitis C virus. Bioorg Med Chem Lett 2011; 21:6007-6012.
21. McGuigan C, Tsang HW, Cahard D, et al. Phosphoramidate derivatives of d4T as inhibitors of HIV: the effect of amino acid variation. Antiviral Res 1997; 35:195-204.